State of New Jersey Common Pension Fund D Increases Stock Holdings in IDEAYA Biosciences, Inc. $IDYA

State of New Jersey Common Pension Fund D grew its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 11.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,827 shares of the company’s stock after buying an additional 10,047 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.12% of IDEAYA Biosciences worth $2,119,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in IDEAYA Biosciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company’s stock worth $123,000 after purchasing an additional 627 shares in the last quarter. CWM LLC increased its position in IDEAYA Biosciences by 33.0% during the 2nd quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after purchasing an additional 782 shares in the last quarter. Swiss National Bank increased its position in IDEAYA Biosciences by 0.8% during the 1st quarter. Swiss National Bank now owns 150,800 shares of the company’s stock worth $2,470,000 after purchasing an additional 1,200 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in IDEAYA Biosciences by 6.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company’s stock worth $349,000 after purchasing an additional 1,214 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in IDEAYA Biosciences by 72.4% during the 2nd quarter. Parallel Advisors LLC now owns 3,260 shares of the company’s stock worth $69,000 after purchasing an additional 1,369 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Barclays assumed coverage on IDEAYA Biosciences in a research report on Thursday, September 4th. They set an “overweight” rating and a $40.00 price objective for the company. JPMorgan Chase & Co. raised their price target on IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Royal Bank Of Canada raised their price target on IDEAYA Biosciences from $38.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Citizens Jmp initiated coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They issued a “mkt outperform” rating and a $41.00 price target on the stock. Finally, Guggenheim initiated coverage on IDEAYA Biosciences in a research note on Thursday, September 18th. They issued a “buy” rating and a $50.00 price target on the stock. Fourteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and an average price target of $44.13.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $32.18 on Thursday. The firm has a market capitalization of $2.82 billion, a P/E ratio of -8.49 and a beta of 0.14. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $33.64. The business’s 50-day simple moving average is $26.69 and its 200-day simple moving average is $23.09.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to analyst estimates of $3.48 million. IDEAYA Biosciences’s quarterly revenue was up NaN% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.68) earnings per share. On average, equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.